Paliperidone Palmitate 3-month Versus 1-month Formulation In Patients With Schizophrenia: A Randomized, Double-blind, Noninferiority Study

被引：0
|
作者：
Savitz, Adam [1 ]
Xu, Haiyan [1 ]
Gopal, Srihari [1 ]
Nuamah, Isaac [1 ]
Ravenstijn, Paulien [2 ]
Janik, Adam [3 ]
Schotte, Alain [2 ]
Hough, David [1 ]
Fleischhacker, Wolfgang W. [4 ]
机构：
[1] Johnson & Johnson Pharmaceut R&D, Neurosci, Titusville, NJ USA
[2] Johnson & Johnson Pharmaceut R&D, Neurosci, Beerse, Belgium
[3] Janssen Cilag, Neurosci, Warsaw, Poland
[4] Innsbruck Med Univ, Dept Psychiat & Psychotherapy, Innsbruck, Austria
来源：
BIOLOGICAL PSYCHIATRY | 2016年 / 79卷 / 09期
关键词：
Paliperidone; 1; monthly; 3; schizophrenia; relapse; PANSS;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
1034
引用
收藏
页码：354S / 354S
页数：1
相关论文
共 50 条
  • [1] Paliperidone Palmitate 3-month vs 1-month Formulation in Patients with Schizophrenia: A Randomized, Double-Blind, Noninferiority Study
    Fleischhacker, W.
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    NEUROPSYCHOPHARMACOLOGY, 2015, 40 : S398 - S399
  • [2] Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Janik, Adam
    Schotte, Alain
    Hough, David
    Fleischhacker, Wolfgang W.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 (07):
  • [3] Paliperidone palmitate 3-month treatment results in symptomatic remission in patients with schizophrenia: a randomized, multicenter, double-blind, and noninferiority study
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2017, 32 (06) : 329 - 336
  • [4] A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia
    Najarian, Dean
    Sanga, Panna
    Wang, Steven
    Lim, Pilar
    Singh, Arun
    Robertson, Mary Jane
    Cohen, Kristin
    Schotte, Alain
    Milz, Ruth
    Venkatasubramanian, Raja
    T'Jollyn, Huybrecht
    Walling, David P.
    Galderisi, Silvana
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2022, 25 (03): : 238 - 251
  • [5] Efficacy and Safety of Paliperidone Palmitate 3-month Formulation in Schizophrenia: a Randomized, Double-blind, Placebo-controlled Study
    Berwaerts, J.
    Liu, Y.
    Gopal, S.
    Nuamah, I.
    Xu, H.
    Savitz, A.
    Coppola, D.
    Schotte, A.
    Remmerie, B.
    Maruta, N.
    Hough, D.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [6] Efficacy and safety of paliperidone palmitate (3-month versus 1-month formulation) in European and non-European patients with schizophrenia
    Savitz, A.
    Xu, H.
    Gopal, S.
    Nuamah, I.
    Ravenstijn, P.
    Hough, D.
    Hargarter, L.
    Fleischhacker, W. W.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S548 - S549
  • [7] Efficacy and Safety of Paliperidone Palmitate (3-Month versus 1-Month formulation) in European and Non-European Patients with Schizophrenia
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Ravenstijn, Paulien
    Hough, David
    Hargartar, Ludger
    Fleischhacker, Wolfgang
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S211 - S211
  • [8] COMPARISON OF PALIPERIDONE PALMITATE 3-MONTH AND PALIPERIDONE PALMITATE 1-MONTH FORMULATION FOR NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: A PHASE 3 NON-INFERIORITY STUDY
    Mathews, Maju
    Gopal, Srihari
    Singh, Arun
    Gogate, Jagadish
    Kim, Edward
    Pungor, Katalin
    SCHIZOPHRENIA BULLETIN, 2018, 44 : S311 - S311
  • [9] Symptomatic Remission Status in Patients with Schizophrenia Treated with Paliperidone Palmitate (1-month and 3-month formulations)
    Savitz, Adam
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Hough, David
    Mathews, Maju
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 354S - 354S
  • [10] COST-EFFECTIVENESS OF PALIPERIDONE PALMITATE 3-MONTH VERSUS 1-MONTH FOR THE TREATMENT OF SCHIZOPHRENIA IN THE UNITED STATES
    Asgharian, A.
    Khushalani, A. S.
    Kremenova, L.
    Karki, S.
    Khan, S.
    Akat, M.
    Magruder, A.
    Blanchette, C. M.
    VALUE IN HEALTH, 2019, 22 : S227 - S227
12345